Pharma readings

By Miguel Tovar

Miguel Tovar
Novartis' migraine drug gets EMA approval
pharmatimes.com
Aimovig becomes Europe’s first treatment specifically designed to prevent migraine
Jul 31, 2018
Miguel Tovar
Pfizer
Pfizer CEO on what happened after Trump tweeted
CNBC - Meg Tirrell
Before he even spoke to the president, Pfizer CEO Ian Read said he knew the best move was to defer the drug giant's early July price increases; a …
Jul 31, 2018
Miguel Tovar
Kyoto team pits iPS cells against Parkinson's disease
japantimes.co.jp - No Author
A Kyoto University research team said Monday it will begin a clinical test this week using induced pluripotent stem cells to treat Parkinson’s …
Jul 30, 2018
Miguel Tovar
Dementia
Highly Anticipated Data On Would-Be Alzheimer's Drug Raises Hope And Questions
Forbes - Ellie Kincaid
How does Biogen Chief Medical Officer Al Sandrock feel after the curtain was lifted on clinical trial data of the experimental Alzheimer’s drug his company is developing with Japanese drugmaker Eisai?
Jul 26, 2018
Miguel Tovar
GSK bets $300 million on genetics as CEO plays down break-up talk
Reuters - Ben Hirschler
LONDON (Reuters) - GlaxoSmithKline aims to turbo-charge its drug discovery engine with a big bet on genetics as its CEO on Wednesday played down the idea of hiving off consumer healthcare, which is a of
Jul 25, 2018
Miguel Tovar
Eisai, Biogen battered by controversy over PhII Alzheimer's study after posting positive results
endpts.com - John Carroll
At first blush, Eisai and Biogen posted the kind of promising data for BAN2401 that might have overcome some doubts about its potential as a …
Jul 25, 2018
Miguel Tovar
23andMe
23andMe Gets $300 Million Boost From GlaxoSmithKline To Develop New Drugs
Forbes - Matthew Herper
GlaxoSmithKline, a London-based drug giant is partnering with 23andMe, the San Francisco genetics startup, to develop new medicines. The companies will split costs and profits equally, and Glaxo will a
Jul 25, 2018
Miguel Tovar
Novartis's Cultural Revolution Will Be AI-Enabled, Desk-Free
Bloomberg - James Paton
When sales staff at drugmaker Novartis AG wake up each morning, an artificial-intelligence program will soon tell them how best to organize their …
November 19
Miguel Tovar
Glaxo’s New Research Chief Loves Big Pharma. Now He Has To Fix It
Forbes - Matthew Herper
It might seem an odd, even brusque question, especially when asked to the CEO of a major pharmaceutical company by a recently hired employee. But it’s how Hal Barron, the new chief scientific officer GlaxoSmithKline,
February 21
Miguel Tovar
https://www.nytimes.com/2018/07/23/us/politics/trump-drug-prices.html
Miguel Tovar
Jul 24, 2018
Miguel Tovar
Top Alzheimer’s researchers hope that near-100 dementia drugs in trials are moving closer to a breakthrough
CNBC - Kelly Song
The search for an Alzheimer’s disease cure has been dogged by pharmaceutical failures, but a network of the world’s top dementia scientists released …
Jul 22, 2018
Miguel Tovar
Investing
Novartis to Pay as Much as $1 Billion for Skin Drug Rights
Bloomberg - Thomas Mulier
Novartis AG agreed to buy the rights to a skin-disease drug from developers Galapagos NV and MorphoSys AG in a deal that could reach $1 billion as …
November 19
Miguel Tovar
Novartis shelves US price increases | Financial Times
Financial Times - Ralph Atkins, Sarah Neville
Swiss drugmaker Novartis has announced that it will shelve price increases for medicines in the US after criticism of the sector from President Donald Trump over rising costs. “We have voluntarily pulled
Jul 18, 2018
Miguel Tovar
Novartis CEO Says It's `Prudent' to Pull Back From Further Price Increases – Bloomberg
Bloomberg
Novartis AG Chief Executive Officer Vas Narasimhan talks about U.S. drug pricing, government health-care policy and plans to spin off the Swiss …
Jul 18, 2018
Miguel Tovar
J&J beats quarterly expectations on drug sales surge, shares jump
Reuters - Manas Mishra
(Reuters) - Johnson & Johnson on Tuesday reported better-than-expected second quarter profit as sales of pharmaceuticals surged 20 percent despite a sharp decline in blockbuster arthritis drug Remicade,
Jul 17, 2018
Miguel Tovar
Investing
Novartis Blockbuster Drug Rebounds, Easing Generics Pressure
Bloomberg - James Paton
Novartis CEO Vas Narasimhan discusses drug pricing, government policy and plans to spin off the Alcon eye-care unit. Novartis AG saw sales of one of …
November 19
Miguel Tovar
Health
Johnson & Johnson CEO defends drug prices, calls for changes in how medical costs are covered
CNBC - Angelica LaVito
Johnson & Johnson CEO Alex Gorsky called for changes in the way prescription drugs are paid for but stopped short of saying pharmaceutical companies …
Jul 17, 2018
Miguel Tovar
Bill Gates
Bill Gates Announces Further Investment In Alzheimer's Research, Taking On Disease Detection
Forbes - Michela Tindera
Microsoft cofounder Bill Gates revealed more of his plan to invest in Alzheimer's disease research on Tuesday. He along with fellow billionaire Leonard Lauder, the Dolby family, the Charles and Helen Foundation
Jul 17, 2018
Miguel Tovar
Big Pharma’s Metabolism Is Slowing Down
Bloomberg Opinion - Max Nisen
Investors need to face the fact that the sector’s best growth days may be behind it. Investors need to face the fact that the sector’s best growth days may be behind it. The biggest players in pharma biotech
Jul 16, 2018
Miguel Tovar
Pfizer
Drugmakers will think twice on price increases after Trump's Pfizer skirmish, says analyst
CNBC
Jul 16, 2018
Miguel Tovar
Novartis Exits Antibiotics Research, Cuts 140 Jobs in Bay Area
Bloomberg - Aziza Kasumov
Novartis AG will shut down its antibacterial and antiviral research operations in the San Francisco Bay area and cut about 140 jobs, joining other …
November 19
Miguel Tovar
Pfizer delays drug price hikes after talking with Trump
Reuters - Yasmeen Abutaleb, Michael Erman
WASHINGTON/NEW YORK (Reuters) - Pfizer Inc (PFE.N) said on Tuesday it was deferring drug price increases for no more than six months after the company’s chief executive officer had an extensive conversation
Jul 11, 2018
Miguel Tovar
China vows to accelerate cancer drug price cuts
China vows to accelerate cancer drug price cuts | Financial Times
Financial Times - Tom Hancock, Wang Xueqiao
Jul 9, 2018
Miguel Tovar
The dementia dilemma
pharmatimes.com
The failure of several Alzheimer’s drug trials in the past year has dampened, but not destroyed, hopes for a cure To the patients desperately waiting …
Jul 9, 2018
Miguel Tovar
This story was written by Matthew Herper and Michela Tindera. The indictment of Theranos founder Elizabeth Holmes, and the barrage of shocking details about her company unearthed by John Carreyrou in …
Venture Capital
Theranos? Whatever. Healthcare Startups Have Raised $15 Billion So Far This Year
Forbes - Matthew Herper
Jul 10, 2018
Miguel Tovar
Hitting cancer early: AstraZeneca's bid to outmaneuver rivals
Reuters - Ben Hirschler
LONDON (Reuters) - AstraZeneca (AZN.L) suffered its biggest daily share price drop a year ago after a key cancer drug trial failed amid feverish speculation the chief executive might quit. FILE PHOTO:
Jul 6, 2018
Miguel Tovar
The Brain
Biogen And Eisai Say Alzheimer's Drug A Success, Reversing Earlier Result
Forbes - Matthew Herper
A complicated new clinical trial could give some hope to Alzheimer's patients and investors in drug companies. But there are lots of devilish details. Drugmakers Biogen and Eisai said the top dose of experimental
Jul 7, 2018
Miguel Tovar
A Risky Drug Approval Lesson
The Wall Street Journal. - The Editorial Board
What the FDA can learn from progress against muscular dystrophy. Some welcome news arrived recently for boys with a condition called Duchenne muscular dystrophy. A new therapy is showing promising results,
Jul 4, 2018
Miguel Tovar
Pharma
Amazon could start selling discounted meds to cash payers as soon as the PillPack deal closes
CNBC - Christina Farr
Now that Amazon has snapped up internet pharmacy PillPack for around $1 billion in cash, how long will it take before consumers can rely on the …
Jul 3, 2018